Bortezomib Suppresses Acute Myelogenous Leukemia Stem-Like KG-1a Cells via NF-κB Inhibition and the Induction of Oxidative Stress

Scientists investigated the anti-acute myelogenous leukemia (AML) activity of bortezomib, emphasizing its anti-leukemic stem cells potential, using KG-1a cells, an AML cell line with stem-like properties.